Imatinib pre-clinical and clinical development
... • Historical narrative of imatinib development • Paper discussion • Imatinib as a paradigm for other targeted therapies (e.g. JAK2 inhibitors) ...
... • Historical narrative of imatinib development • Paper discussion • Imatinib as a paradigm for other targeted therapies (e.g. JAK2 inhibitors) ...
Mechanisms of resistance in CML
... *BCR-ABL mutations Mutations do not always explain resistance May activate different downstream signalling pathways Very sensitive techniques may detect mutations that are not clinically relevant ...
... *BCR-ABL mutations Mutations do not always explain resistance May activate different downstream signalling pathways Very sensitive techniques may detect mutations that are not clinically relevant ...
The Development of Novel Small Molecules as Protein Tyrosine
... drug molecules out of the cell, resulting in a decreased concentration of drugs at the target sites, and therefore a decreased drug efficacy. Imatinib is a substrate of P-glycoprotein, a multidrug resistance protein, while nilotinib is able to inhibit these efflux pumps, such as the human multidrug ...
... drug molecules out of the cell, resulting in a decreased concentration of drugs at the target sites, and therefore a decreased drug efficacy. Imatinib is a substrate of P-glycoprotein, a multidrug resistance protein, while nilotinib is able to inhibit these efflux pumps, such as the human multidrug ...
Shristi Pandey - Chronic Myeloid Leukemia: A look into how genomics is changing the way we treat cancer
... contains a binding site for ATP, which is required for phosphorylation of its substrate. It can only successfully carry out its phosphorylating function if it can bind both ATP and ...
... contains a binding site for ATP, which is required for phosphorylation of its substrate. It can only successfully carry out its phosphorylating function if it can bind both ATP and ...
Chronic Myeloid Leukemia
... treatment of CML was to develop a tyrosine kinase inhibitor, that “turns off’ the active TK in the body, specific to the mutated gene, BRC-ABL The first generation TK inhibitor for CML is imatinib mesylate ...
... treatment of CML was to develop a tyrosine kinase inhibitor, that “turns off’ the active TK in the body, specific to the mutated gene, BRC-ABL The first generation TK inhibitor for CML is imatinib mesylate ...
Glivec
... may be influenced by imatinib. This would occur particularly in pre-pubertal period. The long term effects on growth in children due to prolonged treatment is still not known. However, these patients should be closely monitored. Due to limited number of events obtained from literature and spontaneou ...
... may be influenced by imatinib. This would occur particularly in pre-pubertal period. The long term effects on growth in children due to prolonged treatment is still not known. However, these patients should be closely monitored. Due to limited number of events obtained from literature and spontaneou ...
10117sgp10
... Like imatinib, nilotinib does not inhibit Srckinase and binds only to the inactive conformation of Bcr-Abl, with P-loop folding over the ATP-binding site, and the activation-loop blocking the substrate binding site, to disrupt the ATP-phosphate-binding site and inhibit the catalytic activity of the ...
... Like imatinib, nilotinib does not inhibit Srckinase and binds only to the inactive conformation of Bcr-Abl, with P-loop folding over the ATP-binding site, and the activation-loop blocking the substrate binding site, to disrupt the ATP-phosphate-binding site and inhibit the catalytic activity of the ...